Pfizer CEO eliminates Karen Katen executives
Peter Brandt is the most recent senior management casualty at Pfizer. This 49-year old executive is "retiring" after only six months heading up the U.S. pharmaceutical operation for Pfizer.
Mr. Brandt was promoted from executive vice president of U.S. pharmaceuticals to president as recently as August 15, 2006, when his boss, Pat Kelly, was asked to "look at other career opportunities within Pfizer." Mr. Kelly didn't find any such opportunities and left the company December 31, 2006.
Mr. Kelly's departure appears to have been closely linked to Vice Chairman Karen Katen's decision to "reflect on both her professional and personal goals," and to leave the company to pursue "other opportunities."
Mr. Kindler has now eradicated almost the entire senior U.S marketing team that was in place when he took over as CEO in July 2006. The only person left is Marie-Caroline Sainpy, who is Senior Vice President U.S. Pharmaceuticals marketing and worldwide commercial development. Ms. Sainpy reported to both Brandt and Reed.
Marketing is not the only area affected by Mr. Kindler's broom. He has also appointed Mary McLeod to replace Sylvia Montero, Senior Vice President, Human Resources, who "retired" in January 2007. Ms. McLeod is part of Pfizer's Executive Leadership Team, reporting directly to Mr. Kindler.
Two more "retirements" are Kathy Donovan, Vice President Human Resources, and Beth Levine, general counsel of U.S. pharmaceuticals.
Pfizer's internal rumor mill claims anyone connected with Karen Katen risks losing his/her job.